Low Doses of Advanced Glycation End-Products and Fructosilation Products Promotes Premature Cell Death of Human Cardiac Cells and Increases Drug Resistance of Human Breast Cancer Cells Exposed to Doxorubicin Through NLRP3 and MyD88 Pathways.